U.S. Markets closed

Sucampo's retinitis pigmentosa candidate given orphan designation in Europe

Sucampo Pharmaceuticals has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa. RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today. A form of unoprostone isopropyl is currently approved in the United States. In addition, the FDA has granted orphan drug designation to unoprostone isopropyl for treatment of RP.